Last €83.55 EUR
Change Today +0.443 / 0.53%
Volume 62.0
6COP On Other Exchanges
New York
As of 1:35 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

covidien plc (6COP) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/8/14 - €85.32
52 Week Low
12/27/13 - €48.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COVIDIEN PLC (6COP)

covidien plc (6COP) Related Businessweek News

View More BusinessWeek News

covidien plc (6COP) Details

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company operates through Medical Devices and U.S. Medical Supplies segments. It sells advanced surgical solutions comprising stapling, vessel sealing, fixation (hernia mechanical devices), mesh, hardware and ablation products, and interventional lung and gastrointestinal solutions, as well as general surgical solutions, including surgical instruments, sutures, and electrosurgery products; and peripheral vascular therapies, such as compression, dialysis, venous insufficiency, peripheral stents, directional artherectomy, and other products, as well as neurovascular therapies comprising coils, neurovascular stents, flow diversion products, and access and delivery products to support procedures. The company also offers patient monitoring products, such as sensors, monitors, and temperature management products; airway and ventilation products, including airway, ventilator, and inhalation therapy products, as well as breathing systems; and nursing care products comprising incontinence, wound care, enteral feeding, urology, and suction products. In addition, it sells patient care products, such as operating room supply products and electrodes; original equipment manufacturer products; and SharpSafety products comprising needles, syringes, and sharps disposal products. The company’s products are used primarily by hospitals and ambulatory care centers, as well as alternate site healthcare providers, such as physician offices. It markets its products through direct sales force and third-party distributors. Covidien plc is based in Dublin, Ireland.

39,500 Employees
Last Reported Date: 11/24/14

covidien plc (6COP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $783.5K
Senior Vice President and Group President
Total Annual Compensation: $556.6K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and General Counsel
Total Annual Compensation: $580.9K
Compensation as of Fiscal Year 2013.

covidien plc (6COP) Key Developments

Medtronic, Inc. Acquisition of Covidien plc Receives U.S. Federal Trade Commission Clearance

Medtronic, Inc. and Covidien plc announced the receipt of U.S. Federal Trade Commission (FTC) clearance of Medtronic's proposed acquisition of Covidien. The FTC's clearance follows Medtronic's and Covidien's agreement to a proposed consent order, which includes a commitment to divest certain assets related to Covidien's drug-coated balloon catheter product. As previously announced, a subsidiary of Covidien entered into an agreement to divest these assets to The Spectranetics Corporation and the divestiture is expected to close shortly following completion of Medtronic's acquisition of Covidien. Medtronic and Covidien also entered into a parallel consent agreement regarding the divestiture of assets related to Covidien's drug-coated balloon catheter product with the Canadian Competition Bureau, which also announced its clearance of the transaction. Medtronic's acquisition of Covidien is expected to close in early 2015 after receipt of certain additional regulatory clearances and approvals by both companies' shareholders and sanction by the High Court of Ireland.

Covidien's Fortrex(TM) PTA Balloon Receives FDA 510(k) Clearance

Covidien plc announced U.S. Food and Drug Administration 510(k) clearance for its Fortrex(TM) over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter. The Fortrex(TM) 0.035" OTW PTA balloon catheter --the next-generation high pressure solution to maintain arteriovenous (AV) access--is also intended for use in the peripheral vascular system. A common procedure is to maintain AV access in patients receiving hemodialysis for chronic kidney disease or end stage renal failure. The Fortrex(TM) PTA balloon provides physicians with a high pressure solution to crack the short, fibrous lesions that can block AV access. Furthermore, its unique engineering provides clinicians with: Optimized balloon delivery: Fortrex(TM) PTA balloon's low tip entry profile and robust, flexible shaft design combine to enable tight tracking to the wire and successful navigation in tortuous vessels. Predictable and targeted treatment: The balloon material and design permit shape retention at rated burst pressure, ensuring focused pressure on the lesion for controlled, targeted and predictable treatment. Procedural efficiency: The combination of balloon material and wall thickness enables reliable balloon rewrap and reinsertion along with a top tier deflation time, all of which contribute to the efficiency of the procedure.

Covidien Announces Favorable Results from Iliac Stenosis Study

Covidien plc has announced favorable nine-month results from the DURABILITY Iliac study, conducted with its EverFlex stent, indicated for the treatment of iliac stenosis. The nine-month results confirm the safety and effectiveness of the EverFlex and Protege GPS self-expanding stent systems for the treatment of lesions of the common and external iliac arteries. The EverFlex and Protege GPS self-expanding stent systems demonstrated strong patency rates even in difficult to treat calcified lesions in patients with iliac disease. This data, along with the robust EverFlex stent data in the superficial femoral artery, speaks to the clinical versatility of the system.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6COP:GR €83.55 EUR +0.443

6COP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $74.48 USD +0.41
Becton Dickinson and Co $139.81 USD -0.62
Fresenius Medical Care AG & Co KGaA €60.60 EUR +0.462
Stryker Corp $94.79 USD -1.04
Tyco International Plc $43.16 USD +0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation 6COP Industry Range
Price/Earnings 28.2x
Price/Sales 4.4x
Price/Book 4.6x
Price/Cash Flow 28.0x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVIDIEN PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at